Case Studies

Real-world evidence of delivering strategic insights to the pharmaceutical industry

Inpharmation runs global projects for the majority of top-50 pharmaceutical companies, across all major therapy areas.
Below you can browse a selection of projects showcasing examples of real-world strategic insights Inpharmation delivers.
To receive your full free copy of any case study:
  1. Click on the business scenario that most interests you.
  2. Submit a request via the download instructions.

Strategies to maximize revenue in a crowded market

A top-10 pharma company with an extensive ophthalmology portfolio was competing in crowded and competitive markets. There was a requirement to optimise revenue for different product ranges in 4 countries, 3 therapy areas and across 4 stakeholder groups (including physicians, buyers, and patients).

Read More

IRP launch analysis report

A top-10 pharma company was launching a new medical device and wanted to understand the impact of international reference pricing on their product’s list price development.

Read More

Market Model & Simulator

Market research and market simulator development for a top-10 pharma company with a number of pipeline assets, which could launch with a MDD and/or TRD indication. There was a requirement to model patient numbers and revenue across 7 major markets, for each line of therapy, considering specific comorbidity combinations.

Read More

Optimizing price for new competitor launches

A top-10 pharma company was launching a product within a new therapy class treating rheumatoid arthritis. The class represented a clinical improvement over current treatments on the market, so accurate value based pricing research was vital. The client wanted to know whether they could increase revenue by pricing lower to gain access to earlier lines […]

Read More

Strategies to determine pricing potential of an early asset

A pharma company client had an in-licensing opportunity for a product in development to treat osteoarthritis. They required an analysis to look at the product’s pricing potential in order to determine whether it would be an acceptable investment.

Read More

Multi-indication pricing case study

A pharma company had an add-on biologic to treat COPD, asthma and a number of further indications. The requirement was to analyze the product’s pricing potential. The product had already launched as an add-on for asthma. A recommended optimal pricing strategy was needed for both COPD and further indications. The customer wanted to see whether […]

Read More

Demand market research in a developing therapy area

A top-10 pharma company was launching a product in NASH, a therapy area with no established pharmacological treatments and with few established treatment pathways. Over the coming decade a large number of novel treatments were forecast to enter the market. The new product represented a clinical improvement over many of the new treatments predicted to […]

Read More

Tender pricing research and simulator

In anticipation of a loss of exclusivity event for their market-leading α-TNF biologic, a top-10 pharma company needed a recommendation for the optimal UK discounting strategy, in order to maximize revenue upon launch of the first biosimilar. The purchase of biologics in the UK becomes tender-based upon loss of market exclusivity, therefore the customer needed […]

Read More

Scroll Top